Oslo, Norway, May 21, 2026 - Lytix Biopharma ASA ("Lytix" or the "Company")
today releases its results for the first quarter of 2026. 

Lytix continued to execute on its established development strategy during the
first quarter and post-quarter-end period, with progress across its lead asset
ruxotemitide and broader oncolytic molecule platform. Clinical development
priorities for 2026 and 2027 remain on track, with registrational path planning
advancing for ruxotemitide in neoadjuvant melanoma. 

Ruxotemitide is supported by a strong and consistent clinical foundation across
melanoma and basal cell carcinoma, including evidence of local tumor killing,
systemic immune activation, durable responses, and a manageable safety profile.
The Company is focused on advancing ruxotemitide toward its next stage of
development through disciplined clinical planning, regulatory engagement, and
continued execution. 

Q1 2026 highlights and developments 
> The NeoLIPA Phase II neoadjuvant melanoma study continued to progress: 
-- 20 of 27 patients enrolled as of May 2026 
-- A new clinical site opened at Haukeland to support continued enrollment
momentum and reduce execution risk 
-- Top-line results remain expected in the second half of 2026 
> New ATLAS-IT-05 data were presented at the American Association for Cancer
Research (AACR) Annual Meeting on April 20, 2026 in San Diego. Ruxotemitide
continued to demonstrate clinical and strategic relevance in advanced melanoma: 
-- Tumor shrinkage was observed in distant, non-treated lesions in patients who
had failed prior immunotherapy 
-- Durable responses and disease control were observed in difficult-to-treat
melanoma 
-- Overall survival data further supported the clinical profile of ruxotemitide
in combination with pembrolizumab 
> Additional ATLAS-IT-05 data will be presented at the American Society of
Clinical Oncology (ASCO) Annual Meeting on May 30, 2026 in Chicago 
> Verrica Pharmaceuticals presented new data for ruxotemitide (VP-315), on May
15, 2026 at the Investigative Dermatology Annual Meeting in Chicago 
> Cash and short-term financial investments amounted to NOK 120 million as of
March 31, 2026 
> Total operating expenses amounted to NOK 26.8 million for the first quarter of
2026 

Ruxotemitide remains Lytix's lead development priority. The Company is advancing
the asset in neoadjuvant melanoma through the NeoLIPA study and structured
planning for a potential registrational study. In parallel, Verrica
Pharmaceuticals continue preparations for a registrational Phase 3 trial with
ruxotemitide as a non-surgical treatment for basal cell carcinoma. 

Lytix is continuing to advance LTX-401, its proprietary preclinical oncolytic
small molecule designed for deep-seated tumors. The Company is evaluating the
optimal clinical development strategy for LTX-401 and continues to pursue
partnering discussions to support future value creation. 

Webcast details 
The results will be presented in a webcast with CEO Øystein Rekdal, CFO Gjest
Breistein and CMO Karim Benhadji today. 

Date: Thursday, May 21, 2026 
Time: 14:00 CET 
 
Questions may be submitted in advance to: post@lytixbiopharma.com  

The presentation and Q&A session will be conducted in English. You can view the
live event by registering here: https://qcnl.tv/p/s6roJjTDW6gVSNwfqof5Rw 

A recording will be available after the event at: 
https://www.lytixbiopharma.com/investors/reports-and-presentations/financial-rep
orts   

For more information, please contact: 
Gjest Breistein, CFO 
+47 952 60 512 
gjest.breistein@lytixbiopharma.com 


About Lytix:  
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide, formerly LTX-315, is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as monotherapy and combination therapy.
Lytix is listed on Euronext Growth Oslo under the ticker LYTIX. 

For more information, visit www.lytixbiopharma.com 
 is listed on Euronext Growth Oslo under the ticker LYTIX. \
\
For more information\, visit www.lytixbiopharma.com \